Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy uniQure N-V stock | $39.86

Own uniQure N-V stock in just a few minutes.

Fact checked

uniQure N.V is a biotechnology business based in the US. uniQure N-V shares (QURE) are listed on the NASDAQ and all prices are listed in US Dollars. uniQure N-V employs 248 staff and has a trailing 12-month revenue of around USD$5.3 million.

How to buy shares in uniQure N-V

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for uniQure N-V. Find the stock by name or ticker symbol: QURE. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until uniQure N-V reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$39.86, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of uniQure N-V, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of uniQure N-V. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

uniQure N-V share price

Use our graph to track the performance of QURE stocks over time.

uniQure N-V shares at a glance

Information last updated 2020-10-20.
Latest market closeUSD$39.86
52-week rangeUSD$34.38 - USD$76.6869
50-day moving average USD$38.2766
200-day moving average USD$48.7476
Wall St. target priceUSD$74
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.795

Buy uniQure N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy uniQure N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

uniQure N-V price performance over time

Historical closes compared with the close of $39.86 from 2021-01-11

1 week (2021-01-08) -2.73%
1 month (2020-12-15) -16.72%
3 months (2020-10-15) 12.00%
6 months (2020-07-15) -11.22%
1 year (2020-01-15) -42.70%
2 years (2019-01-15) 25.70%
3 years (2018-01-12) 126.61%
5 years (2016-01-15) 150.69%

uniQure N-V financials

Revenue TTM USD$5.3 million
Gross profit TTM USD$-87,456,000
Return on assets TTM -26.82%
Return on equity TTM -68.21%
Profit margin 0%
Book value $5.982
Market capitalisation USD$1.7 billion

TTM: trailing 12 months

Shorting uniQure N-V shares

There are currently 4.0 million uniQure N-V shares held short by investors – that's known as uniQure N-V's "short interest". This figure is 8.7% up from 3.7 million last month.

There are a few different ways that this level of interest in shorting uniQure N-V shares can be evaluated.

uniQure N-V's "short interest ratio" (SIR)

uniQure N-V's "short interest ratio" (SIR) is the quantity of uniQure N-V shares currently shorted divided by the average quantity of uniQure N-V shares traded daily (recently around 445170.52280311). uniQure N-V's SIR currently stands at 8.99. In other words for every 100,000 uniQure N-V shares traded daily on the market, roughly 8990 shares are currently held short.

However uniQure N-V's short interest can also be evaluated against the total number of uniQure N-V shares, or, against the total number of tradable uniQure N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case uniQure N-V's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 uniQure N-V shares in existence, roughly 90 shares are currently held short) or 0.1007% of the tradable shares (for every 100,000 tradable uniQure N-V shares, roughly 101 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against uniQure N-V.

Find out more about how you can short uniQure N-V stock.

uniQure N-V share dividends

We're not expecting uniQure N-V to pay a dividend over the next 12 months.

uniQure N-V share price volatility

Over the last 12 months, uniQure N-V's shares have ranged in value from as little as $34.38 up to $76.6869. A popular way to gauge a stock's volatility is its "beta".

QURE.US volatility(beta: 1.12)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while uniQure N-V's is 1.1208. This would suggest that uniQure N-V's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

uniQure N-V overview

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site